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Abstract
Metastasis represents one of the main clinical challenge in cancer treatment since it is
associated with the majority of deaths. Recent technological advances allow quantification
of the dynamics of the process by means of noninvasive techniques such as longitudinal
tracking of bioluminescent cells. The metastatic process was simplified here into two essential
components – dissemination and colonization – which were mathematically formalized in
terms of simple quantitative laws. The resulting mathematical model was confronted to
in vivo experimental data of spontaneous metastasis after primary tumor resection. We
discuss how much information can be inferred from confrontation of theories to the data
with emphasis on identifiability issues. It is shown that two mutually exclusive assumptions
for the secondary growth law (namely same or different from the primary tumor growth law)
could fit equally well the data. Similarly, the fractal dimension coefficient in the dissemination
law could not be uniquely determined from data on total metastatic burden only. Together,
these results delimitate the range of information that can be recovered from fitting data of
metastatic growth to already simplified mathematical models.
1 Introduction
Metastasis (from the greek µετα´ = change and στα´σιζ = place) is a process by which
secondary tumors emerge at distant sites from the location of the primary disease [Weiss, 2000].
This is the result of cells detaching the primary tumor, invading the surrounding tissue, traveling
to distant sites (mostly through hematogenous ways) before establishing secondary colonies in
distant organs, such as the lungs or the liver (the two organs most often affected nowadays)
[Talmadge and Fidler, 2010, Weiss, 2000]. Despite very complex processes happening at various
biological scales, the phenomenon can be summarized into two major phases: dissemination and
colonization [Chaffer and Weinberg, 2011, Steeg, 2006].
In recent years, novel experimental techniques shed new lights on the process of metas-
tasis [Sahai, 2007]. On the one hand, the advent of molecular biology revealed the exis-
tence and importance of several processes, such as the epithelial-to-mesenchymal transition and
its regulation [Chaffer and Weinberg, 2011, Valastyan and Weinberg, 2011, Nguyen et al., 2009]
or the association between genetic signatures and the probability of metastatic relapse
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[van de Vijver et al., 2002], of crucial importance considering that metastases are the ones that
ultimately kill cancer patients. On the other hand, other processes were discovered that hap-
pen at the system scale of the organism. These include the distant suppression of metastatic
growth by endogenous inhibitors of angiogenesis [O’Reilly et al., 1994] or the self-seeding phe-
nomenon [Norton and Massague´, 2006, Kim et al., 2009]. Quantification of the dynamics of
these processes is now conceivable thanks to non-invasive experimental techniques that allow
to longitudinally track the evolution of the disease [Francia et al., 2011]. One of these consist
in transfecting cancer cells with an excitable protein such as the luciferin. After orthotopic
implantation of these cells in mice, when the enzyme luciferase is subsequently injected to the
animals, the cells emit photons, and the emission intensity can be externally recorded.
The advent of these new experimental techniques generates new data that call for quan-
titative models in order to analyze them and infer general laws of the disease development.
Maybe due to the relative scarcity of data about the dynamics of metastasis, relatively few
mathematical models have been proposed that could be used to test hypotheses and quantify
aspects of the process [Michor et al., 2006, Bartoszyn´ski, 1987, Hanin, 2013, Retsky et al., 1997,
Yorke et al., 1993, Hartung et al., 2014, Haeno et al., 2012]. Of note however, in 2000, Iwata,
Kawasaki and Shigesada proposed a model particularly well suited for description of the time
dynamics of a population of secondary tumors [Iwata et al., 2000]. This model can be easily
adapted to longitudinal data of total metastatic burden and has been recently shown able to
fit such data in several animal models [Hartung et al., 2014, Benzekry et al., 2015]. Based on
one of this study, we will focus here on the identifiability aspects of particular coefficients of the
model, respectively related to the growth and dissemination laws. In other words, our aim is to
determine what can and what cannot be discriminated based on the data that we dispose on
one hand, and the formalism of [Iwata et al., 2000] on the other.
2 Model
The models that were confronted in this study were largely inspired by the initial model of
Iwata, Kawasaki and Shigesada [Iwata et al., 2000]. We refer to [Benzekry et al., 2015] for a
detailed description. Briefly, dynamics of the primary tumor volume Vp(t) at time t is defined
by the following Cauchy problem: ®
dVp
dt = gp(Vp(t))
Vp(t = 0) = Vi
(1)
where gp is the primary tumor (PT) growth law (here, either Gompertz or exponential) and Vi is
the number of cells at injection, converted into the appropriate unit (either photons per seconds
for bioluminescence data or mm3 for caliper-measured volumes). Metastatic development is then
defined by two components: the dissemination law d(Vp) and the colonization (or growth) law
g(v) for a tumor of volume v. These shall be discussed in details below. Specification of these
two laws allows to write a partial differential equation for the time evolution of the density of
metastases ρ(t, v) structured by the size v of the lesions [Iwata et al., 2000]:
∂tρ(t, v) + ∂v(ρ(t, v)g(v)) = 0 t ∈]0,+∞[, v ∈]V0,+∞[
g(V0)ρ(t, V0) = d(Vp(t)) t ∈]0,+∞[
ρ(0, v) = 0 v ∈]V0,+∞[
(2)
2
where V0 is the size at which metastasis are born (here assumed to be the size of one cell).
For calibration of the conversion ratio from number of cells to bioluminescence, we refer the
reader to [Benzekry et al., 2015]. In (2), the first equation expresses conservation of the number
of metastases when growing in size, the second equates the entering flux of new tumors with
the rate of (successful) dissemination from the primary tumor and the last one is the initial
condition. From (2), the main quantity of interest for confrontation to bioluminescence data is
the total metastatic burden:
M(t) =
∫ +∞
V0
vρ(t, v)dv =
∫ t
0
d (Vp(t− s))V (s)
where s 7→ V (s) is a solution of the Cauchy problem (1) with g instead of gp and V0 instead of
Vi.
3 Results
We investigated growth laws being either Gompertz (or Gomp-Exp) or exponential. The
dissemination law was assumed to have the following expression (see below for modeling details)
d(Vp) = µV γp
and identifiability of γ was considered. When not otherwise specified, γ = 1.
3.1 Growth law
Material and methods generating the data employed here are extensively described in
[Benzekry et al., 2015]. For the growth of LM2-4luc+ cells orthotopically xenografted in the
mammary fat pad of severe combined immune-deficient mice, as employed here, it had been
previously demonstrated that the growth kinetics can be accurately described using the Gom-
pertz model [Benzekry et al., 2014], with expression gp(v) = v
Ä
α− β ln
Ä
v
V0
ää
. Arguing that for
small volumes (such as the one of metastases at initiation), the specific growth rate (i.e. g(v)v )
is bounded, and choosing as a reasonable bound the in vitro specific growth rate, we rather
considered the Gomp-Exp model [Wheldon, 1988]:
gp(v) = min
Å
λv, v
Å
α− β ln
Å
v
V0
ããã
where λ is the in vitro proliferation rate, retrieved from preliminary experiments (see
[Benzekry et al., 2015]). We then investigated what structural and parametrical shape of the
secondary growth coefficient g(v) would better fit the data, while ensuring reasonable identifi-
ability of its parameters. Four scenarii were considered: A) same growth between the PT and
the metastases, B) Gomp-Exp for the PT and exponential for the metastases, C) Gomp-Exp
for both the PT and the metastases, with α constrained to be identical for the two and D)
Gomp-Exp for both the PT and the metastases, with both parameters α and β allowed to differ
between the PT and the metastases. To use the information at the population level and increase
robustness of the parameters estimation (which was found very poor on individual growth curves
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alone), we used the nonlinear mixed-effects statistical framework to fit the data [Lavielle, 2014].
Briefly, it consists in maximizing the likelihood of the entire dataset over all individuals, under
the assumption of a distribution of the parameters within the population (which was assumed
here to be lognormal). Plain and dashed lines in Figure 1 are respectively the medians and 10th
and 90th percentiles of the outputs of simulations of the model under this distribution.
Selection of the best model was made based on the following considerations: i) visual accu-
racy of the fit (A-D in Figure 1) and statistical criteria of goodness-of-fit such as the Akaike
Information Criterion (F in Figure 1), but also ii) practical identifiability of the parameters, as
quantified by the normal standard errors reported in Figure 1.E. As can be observed, model B)
has to be rejected for inaccuracy, while model D is clearly over-parameterized (see the values
of criteria in Figure 1.F and more importantly the uncertainty on the parameters estimation,
especially the normalized standard error on µ in Figure 1.E). With similar visual accuracy of
the population fits (also observable in individual fits of particular mice, results not shown here),
the model C) nevertheless generated substantially higher uncertainty on the parameter estima-
tion, especially parameter µ, with respective normalized standard error of 26.5% for the ”same
growth” model and 72.1% for the ”different growth with alpha fixed” model. Additionally, prob-
ably due to sharper estimation of the parameters, predictive performances were improved with
the ”same growth” model (results not shown). On the other hand, results of the AIC suggest
that the addition of one degree of freedom in model C) yields significant improvement of the
goodness-of-fit.
However, under the model C), the difference inferred for parameter β translated into minor
differences between primary and secondary growth. Together, these results suggest that, al-
though definitive determination of the relationship between the primary and secondary tumor
growth law cannot be assessed based only on data on PT and MB growth, the theory assuming
equality of the growth rates is conceivable and the most parsimonious.
3.2 Dissemination law
With the growth law fixed to the ”same growth” model, we investigated determination of
the shape of the dissemination law d(Vp). It has been proposed to have the following shape
[Iwata et al., 2000]:
d(Vp) = µV γp (3)
with µ a parameter quantifying the per cell and per day probability of generating a new metasta-
sis, and γ possibly related to the fractal dimension of the primary tumor vasculature. Parameter
γ thus controls the number of cells that are susceptible to leave the tumor while µ can be linked
to a more intrinsic metastatic potential of the disease, aggregating chance of success to mul-
tiple steps of the metastatic cascade (including genetic mutations, epithelial-to-mesenchymal
transition, blood vessel intravasation, survival in transit, extravasation at the distant site and
colonization of the new organ’s parenchyma).
We wondered whether the value of γ could be determined given the data we dispose. As
appears in the results reported in Figure 2, several values generated relatively similar fits. Shown
are only three representative values between 0 and 1 but every value of γ investigated gave similar
curves. Although the value of γ = 0.5 generated a slightly better fit than γ = 0 or γ = 1, we
did not consider this strong enough to support rejection of either of the possibilities for γ. We
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Model Par. Unit Median value (CV) NSE (%)
Diff growth alpha fixed
αP day
−1 0.605 (9.83) 3.57
βP day
−1 0.0786 (12.2) 4.86
µ cell−1 · day−1 3.01e-09 (820) 72
β day−1 0.0816 (15.7) 5.06
Same growth
α day−1 0.664 (16.3) 4.77
β day−1 0.0893 (21.3) 6.21
µ cell−1 · day−1 4.43e-11 (176) 26.5
Diff growth Exp
αP day
−1 0.61 (9.88) 3.8
βP day
−1 0.0796 (11.6) 5.08
m mm−3 · day−1 107 (3.55e+03) 62.3
a day−1 0.114 (46.8) 11.7
Diff growth
αP day
−1 0.625 (11.4) 4.06
βP day
−1 0.0822 (13.4) 5.31
m cell−1 · day−1 0.0075 (4.43e+04) 5.04e+05
α day−1 1.29 (40.6) 54.4
β day−1 0.071 (44.5) 36.6
Data primary tumor
Median model primary tumor
10th and 90th percentiles model primary tumor
Data metastatic burden
Median model metastatic burden
10th and 90th percentiles model metastatic burden
F
Model AIC BIC #
Diff growth alpha fixed 5505[1] 5517[1] 4
Same growth 5525[2] 5533[2] 3
Diff growth Exp 5532[3] 5543[3] 4
Diff growth 5545[4] 5561[4] 5
1
Figure 1: Population fits of the breast xenograft data under different growth theories. A: Same
growth = same Gompertz growth parameters (α and β) for primary and secondary tumors.B:
Different growth Exp = exponential growth law for the metastases. C: Different growth alpha
fixed = for each animal, same value of parameter α was imposed while value of β was allowed
to vary between the PT and the secondary tumors. D: Different growth = the two Gompertz
parameters α and β were allowed to vary between the PT and the metastases. E: Parameters
estimates under the two different models, and corresponding normalized standard errors. F: Sta-
tistical goodness-of-fit metrics for the various models. PT = Primary Tumor. MB = Metastatic
Burden. CV = coefficient of variation (defined as medianstandard deviation × 100). NSE = normalized
standard error (expressed in percent). AIC = Akaike Information Criterion. BIC = Bayesian
Information Criterion. # = number of parameters.
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Figure 2: Population fits of the ortho-surgical metastasis animal models for a dissemination
coefficient d(Vp) = µVγp and various values of γ
therefore concluded that the precise value of γ in (3) could not be decided based on our data
consisting on PT and post-surgery metastatic growth.
4 Discussion
Any data-based modeling inference is limited by two major aspects: 1) the richness of the
data and 2) the complexity of the model. Only when taking into account the balance between
these two aspects can we reject hypotheses and thus improve our knowledge about natural
mechanisms.
Metastasis is a complex process that remains poorly understood, especially during the col-
onization phase (after extravasation at the distant site). Using a mathematical formalism of
basic laws of the process (dissemination and growth), we evaluated here the limits of what
can be learned from longitudinal noninvasive data of post-surgery spontaneous metastasis. Our
results demonstrated that similar growth between the primary tumor and the metastases was
a conceivable theory for metastatic development in a xenograft breast cancer animal model.
Exponential growth of the metastases had to be rejected while, on the other hand, a model
with different growth of the metastases could also explain the data. Further quantification of
metastatic growth are required to discriminate between the ”same growth” and ”different growth
alpha fixed” models, although growth of secondary tumors was not substantially different when
inferred under the second model. To this end, longitudinal follow up of individual metastatic le-
sions in mice using magnetic resonance imaging might be of great help [Baratchart et al., 2015].
Non-uniqueness was also observed for the values of the fractal dimension of the vasculature in
the dissemination coefficient able to fit the data. This justifies the use of γ = 1, i.e. the simplest
theory (all cells within the primary tumor have equal probability of generating a metastasis)
to describe the data [Benzekry et al., 2015]. Additional data are required to discriminate if a
particular value of γ is better adapted for specification of the dissemination law.
Together, our results demonstrate that, even with a simple mathematical framework (3 de-
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grees of freedom in the most adapted version) and relatively rich data, several mutually exclusive
models can fit data of total metastatic burden dynamics, leaving open the question of definitive
determination of the growth and dissemination laws of metastatic development.
References
[Baratchart et al., 2015] Baratchart, E., Benzekry, S., Bikfalvi, A., Colin, T., Cooley, L. S.,
Pineau, R., Ribot, E., Saut, O., and Souleyreau, W. (2015). Computational modelling of
metastasis development in renal cell carcinoma. to appear in PloS Comput Biol.
[Bartoszyn´ski, 1987] Bartoszyn´ski, R. (1987). A modeling approach to metastatic progression
of cancer. In Thompson, J. R. and Brown, B. W., editors, Cancer Modeling, pages 237–267.
New York.
[Benzekry et al., 2014] Benzekry, S., Lamont, C., Beheshti, A., Tracz, A., Ebos, J. M. L., Hlatky,
L., and Hahnfeldt, P. (2014). Classical mathematical models for description and prediction
of experimental tumor growth. PLoS Comput Biol, 10(8):e1003800.
[Benzekry et al., 2015] Benzekry, S., Tracz, A., Mastri, M., Corbelli, R., Barbolosi, D., and
Ebos, J. M. L. (2015). Modeling spontaneous metastasis following surgery: An in vivo/in
silico approach. to appear in Cancer Res.
[Chaffer and Weinberg, 2011] Chaffer, C. L. and Weinberg, R. A. (2011). A perspective on
cancer cell metastasis. Science, 331(6024):1559–1564.
[Francia et al., 2011] Francia, G., Cruz-Munoz, W., Man, S., Xu, P., and Kerbel, R. S. (2011).
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev
Cancer, 11(2):135–141.
[Haeno et al., 2012] Haeno, H., Gonen, M., Davis, M. B., Herman, J. M., Iacobuzio-Donahue,
C. A., and Michor, F. (2012). Computational Modeling of Pancreatic Cancer Reveals Kinetics
of Metastasis Suggesting Optimum Treatment Strategies. Cell, 148(1-2):362–375.
[Hanin, 2013] Hanin, L. (2013). Seeing the invisible: how mathematical models uncover tumor
dormancy, reconstruct the natural history of cancer, and assess the effects of treatment.
Advances Exp Med Biol, 734(Chapter 12):261–282.
[Hartung et al., 2014] Hartung, N., Mollard, S., Barbolosi, D., Benabdallah, A., Chapuisat,
G., Henry, G., Giacometti, S., Iliadis, A., Ciccolini, J., Faivre, C., and Hubert, F. (2014).
Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-
bearing mice. Cancer Res, 74(22):6397–6407.
[Iwata et al., 2000] Iwata, K., Kawasaki, K., and Shigesada, N. (2000). A Dynamical Model for
the Growth and Size Distribution of Multiple Metastatic Tumors. J Theor Biol, 203(2):177–
186.
[Kim et al., 2009] Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H. F.,
Norton, L., and Massague´, J. (2009). Tumor self-seeding by circulating cancer cells. Cell,
139(7):1315–26.
7
[Lavielle, 2014] Lavielle, M. (2014). Mixed Effects Models for the Population Approach. Models,
Tasks, Methods and Tools. CRC Press.
[Michor et al., 2006] Michor, F., Nowak, M. A., and Iwasa, Y. (2006). Stochastic dynamics of
metastasis formation. J Theor Biol, 240(4):521–530.
[Nguyen et al., 2009] Nguyen, D. X., Bos, P. D., and Massague´, J. (2009). Metastasis: from
dissemination to organ-specific colonization. Nat Rev Cancer, 9(4):274–284.
[Norton and Massague´, 2006] Norton, L. and Massague´, J. (2006). Is cancer a disease of self-
seeding? Nat Med, 12(8):875–878.
[O’Reilly et al., 1994] O’Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A.,
Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994). Angiostatin: a novel
angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Cell, 79(2):315–328.
[Retsky et al., 1997] Retsky, M. W., Demicheli, R., Swartzendruber, D. E., Bame, P. D., Ward-
well, R. H., Bonadonna, G., Speer, J. F., and Valagussa, P. (1997). Computer simulation of
a breast cancer metastasis model. Breast Cancer Res Treat, 45(2):193–202.
[Sahai, 2007] Sahai, E. (2007). Illuminating the metastatic process. Nat Rev Cancer, 7(10):737–
749.
[Steeg, 2006] Steeg, P. S. (2006). Tumor metastasis: mechanistic insights and clinical challenges.
Nat Med, 12(8):895–904.
[Talmadge and Fidler, 2010] Talmadge, J. E. and Fidler, I. J. (2010). AACR centennial series:
the biology of cancer metastasis: historical perspective. Cancer Res, 70(14):5649–69.
[Valastyan and Weinberg, 2011] Valastyan, S. and Weinberg, R. A. (2011). Tumor metastasis:
molecular insights and evolving paradigms. Cell, 147(2):275–92.
[van de Vijver et al., 2002] van de Vijver, M. J., He, Y. D., van ’t Veer, L. J., Dai, H., Hart, A.
A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., Parrish,
M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H.,
Rodenhuis, S., Rutgers, E. T., Friend, S. H., and Bernards, R. (2002). A Gene-Expression
Signature as a Predictor of Survival in Breast Cancer. N Engl J Med, 347(25):1999–2009.
[Weiss, 2000] Weiss, L. (2000). Concepts of Metastasis. Cancer Metastasis Rev., 19(3-4):219–
234.
[Wheldon, 1988] Wheldon, T. E. (1988). Mathematical models in cancer research. Hilger Bristol.
[Yorke et al., 1993] Yorke, E. D., Fuks, Z., Norton, L., Whitmore, W., and Ling, C. C. (1993).
Modeling the development of metastases from primary and locally recurrent tumors: compar-
ison with a clinical data base for prostatic cancer. Cancer Res, 53(13):2987–2993.
8
